Clinical Trials Browser

Phase 2 × Bevacizumab × Breast × Clear all

NCT05398861 2026-04-16

Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

Phase 2 Recruiting

HER-2 Negative Breast Cancer

NCT05769010 2026-04-01

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

Phase 2 Recruiting

Breast Neoplasms

NCT07446452 2026-03-03

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

Phase 2 Recruiting

HER2-low Breast Cancer

NCT06976944 2026-02-23

PRELUDE

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07359404 2026-01-22

Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC

Phase 2 Enrolling by invitation

Advanced Breast Cancer

NCT07351487 2026-01-20

Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT05180006 2025-12-01

BIS-Program

Phase 2 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06271837 2025-10-22

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

Phase 2 Recruiting

Breast Neoplasms

NCT00861705 2025-09-30

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Phase 2 Completed

454 enrolled 23 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT07150208 2025-09-02

THUMB

Phase 2 Not yet recruiting

Breast Cancer With Brain Metastasis

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT07065435 2025-07-15

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

Phase 2 Recruiting

Breast Neoplasms

NCT02436993 2025-07-14

Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab

Phase 2 Active not recruiting

Breast Neoplasms

NCT05192798 2025-02-27

Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT06786026 2025-02-06

QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

Phase 2 Active not recruiting

Breast Neoplasms

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT06539559 2024-08-06

Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer

Phase 2 Not yet recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT04303988 2024-07-18

A Phase II Study of Triple-negative Breast Cancer Brain Metastases.

Phase 2 Recruiting

Breast Neoplasms

NCT03395899 2024-06-18

ECLIPSE

Phase 2 Completed

Breast Neoplasms

NCT04408118 2024-06-04

ATRACTIB

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04739670 2024-03-01

BELLA

Phase 2 Unknown

Recurrence, Triple Negative Breast Neoplasms

NCT00618657 2024-02-28

Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting

Phase 2 Completed

127 enrolled 12 charts

Breast Neoplasms

NCT02456857 2024-02-13

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

Phase 2 Completed

17 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT04395989 2023-12-22

FUTURE-SUPER

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT00679029 2023-12-11

Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

Phase 2 Terminated

15 enrolled 9 charts

Breast Neoplasms

NCT06125080 2023-11-09

UTILIZABLE

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT03961698 2023-08-14

MARIO-3

Phase 2 Unknown

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms

NCT00608972 2023-02-08

Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer

Phase 2 Completed

31 enrolled 11 charts

Breast Neoplasms

NCT00773695 2023-01-09

A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00530868 2022-10-21

Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer

Phase 2 Completed

75 enrolled 9 charts

Breast Neoplasms

NCT05357417 2022-09-16

Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases

Phase 2 Unknown

Breast Neoplasms

NCT01989780 2022-08-04

BOOSTER

Phase 2 Completed

Breast Neoplasms

NCT05303038 2022-06-09

Castle06(BC)

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT04389073 2022-02-25

Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine

Phase 2 Unknown

Breast Neoplasms

NCT00925652 2022-01-19

ABCDE

Phase 2 Terminated

55 enrolled 11 charts

Breast Neoplasms

NCT00405938 2021-11-18

Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer

Phase 2 Completed

79 enrolled 7 charts

Breast Neoplasms

NCT00444535 2021-10-25

Lapatinib and Bevacizumab for Metastatic Breast Cancer

Phase 2 Completed

52 enrolled 13 charts

Breast Neoplasms, Osteitis Deformans

NCT00464646 2021-10-25

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

Phase 2 Completed

105 enrolled 17 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00580333 2021-05-26

Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer

Phase 2 Completed

51 enrolled 7 charts

Breast Neoplasms

NCT00546156 2021-05-18

Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer

Phase 2 Completed

104 enrolled 7 charts

Breast Neoplasms

NCT02185352 2021-05-07

A-Plus

Phase 2 Unknown

Brain Neoplasms, Breast Neoplasms

NCT00723125 2021-04-29

Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer

Phase 2 Completed

60 enrolled 7 charts

Breast Neoplasms

NCT00365417 2021-04-13

Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer

Phase 2 Completed

45 enrolled 15 charts

Breast Neoplasms

NCT00461773 2021-03-16

Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer

Phase 2 Terminated

5 enrolled 7 charts

Breast Neoplasms

NCT03577743 2021-03-09

Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT00536939 2020-09-24

Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer

Phase 2 Terminated

2 enrolled 5 charts

Breast Neoplasms

NCT00217672 2020-08-05

Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer

Phase 2 Completed

76 enrolled 11 charts

Breast Neoplasms

NCT00472693 2020-04-09

Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00394082 2019-11-25

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

Phase 2 Completed

50 enrolled 17 charts

Breast Neoplasms